(DOTA(0)-Phe(1)-Tyr(3))octreotide (SMT 487)

Subscribe to Selected New Research on (DOTA(0)-Phe(1)-Tyr(3))octreotide

34 relevant articles (3 outcomes, 6 trials/studies) found for this Bio-Agent

Description: DOTA - 1,4,7,10-tetraazacyclododecanetetracetic acid; structure given in first source; may be labelled with various radioisotopes

Also Known As:

SMT 487; DOTATOC; SMT-487

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 58

Macrocyclic Compounds: 1

Cyclic Peptides: 41

Octreotide: 3220

(DOTA(0)-Phe(1)-Tyr(3))octreotide: 34

Amino Acids, Peptides, and Proteins

Peptides: 16074

Cyclic Peptides: 41

Octreotide: 3220

(DOTA(0)-Phe(1)-Tyr(3))octreotide: 34

Experts

1.	Hofer, S: 2 articles (04/2002 - 11/2001)
2.	Freitag, P: 2 articles (04/2002 - 11/2001)
3.	Eichhorn, K: 2 articles (04/2002 - 11/2001)
4.	Merlo, A: 2 articles (04/2002 - 11/2001)
5.	Zabel-du Bois, Angelika: 1 article (05/2006)
6.	Schulz-Ertner, Daniela: 1 article (05/2006)
7.	Hoess, Angelika: 1 article (05/2006)
8.	Haberkorn, Uwe: 1 article (05/2006)
9.	Henze, Marcus: 1 article (05/2006)
10.	Milker-Zabel, Stefanie: 1 article (05/2006)

Related Diseases

1.	Neoplasms (Cancer) 02/15/2002 - "RESULTS: These studies showed that untreated animals and animals treated with no virus and 500 microCi [(90)Y]-SMT 487 had median tumor quadrupling times of 16 and 25 days, respectively" 02/15/2002 - "For therapy studies, mice bearing established subcutaneous A-427 tumors were given two intratumoral injections of AdSSTr2 1 week apart, followed by an intravenous injection of 400 microCi or 500 microCi [(90)Y]-SMT 487 at 2 and 4 days after each adenoviral administration" 05/01/2006 - "In all patients [68Ga]-DOTATOC-PET delivered additional information concerning tumor extension" 01/01/2003 - "In two patients with previously known localization of tumor, dynamic PET scans after intravenous bolus-injection of 181+/-17 MBq [68Ga]-DOTATOC until 120 minutes post-injection were acquired" 02/15/2002 - "Mice administered AdSSTr2 and either 400 microCi or 500 microCi of [(90)Y]-SMT 487 demonstrated significantly longer median tumor quadrupling times of 40 and 44 days, respectively (P < 0.02)" Get all the results and reference details, order at left...
2.	Meningioma (Meningiomas) 05/01/2006 - "Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET." 05/01/2006 - "CONCLUSION: These data demonstrate that [68Ga]-DOTATOC-PET improves target definition for FSRT in patients with intracranial meningiomas" 07/01/2001 - "We acquired dynamic PET images over 120 min after intravenous injection of 175 MBq [68Ga]DOTATOC in 3 patients suffering from 8 meningiomas (WHO I degrees; 7- to 25-mm diameter)" 07/01/2001 - "CONCLUSION: According to our initial experiences, [68Ga]DOTATOC seems to be a very promising new PET tracer for imaging SSTRs even in small meningiomas, offering excellent imaging properties and a very high tumor-to-background ratio." 05/01/2006 - "Because meningiomas show a high expression of somatostatin receptor subtype 2, somatostatin analogs such as DOTATOC offer the possibility of receptor-targeted imaging" Get all the results and reference details, order at left...
3.	Adenocarcinoma 02/01/2007 - "CONCLUSIONS: In conclusion, at the same absorbed dose, [(213)Bi]DOTATOC is therapeutically more effective in decreasing survival than is [(177)Lu]DOTATOC in human pancreatic adenocarcinoma cells due to its comparatively higher RBE." Get all the results and reference details, order at left...
4.	Neoplasm Metastasis (Metastasis) 12/01/2001 - "This study addressed the production of gallium-68 DOTATOC, its biokinetics and its clinical performance in detecting SMS-positive tumours and metastases" 07/01/2006 - "In contrast, none of the eight metastases which were positive on FDG PET showed any DOTATOC uptake" 01/01/2003 - "CONCLUSIONS: According to our initial experiences in a limited number of patients, [68Ga]-DOTATOC is a promising PET tracer for imaging neuroendocrine tumors and their metastases" 01/01/2003 - "Both [111In]-DTPAOC-SPECT and [68Ga]-DOTATOC-PET were less sensitive in the detection of liver metastases of neuroendocrine tumors compared to computerized tomography CT because they showed a lower uptake than the surrounding liver tissue" 07/01/1997 - "This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the beta-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization" Get all the results and reference details, order at left...
5.	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/01/2008 - "One of these is 90 Y-Dotatoc; we have already used it in patients with neuroendocrine tumors of the lung" 10/01/2003 - "(90)Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical currently under investigation as a therapeutic option for neuroendocrine tumors" 01/01/2003 - "CONCLUSIONS: According to our initial experiences in a limited number of patients, [68Ga]-DOTATOC is a promising PET tracer for imaging neuroendocrine tumors and their metastases" 01/01/2003 - "Both [111In]-DTPAOC-SPECT and [68Ga]-DOTATOC-PET were less sensitive in the detection of liver metastases of neuroendocrine tumors compared to computerized tomography CT because they showed a lower uptake than the surrounding liver tissue" 04/01/2006 - "(131)I-Metaiodobenzylguanidine (MIBG) and (90)Y-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) have been used as radiotherapeutic agents for treating neuroendocrine tumors" Get all the results and reference details, order at left...
12 Diseases and 34 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Somatostatin Receptors (Somatostatin Receptor)
2.	3-Tyr-octreotide
3.	Octreotide (Sandostatin)
4.	yttrium(III)- 1,4,7,10- tetraazacyclotetradecane- N,N',N'',N'''- tetraacetic acid
5.	Pentetic Acid (DTPA)
6.	Somatostatin (Somatotropin Release-Inhibiting Factor)
7.	SDZ 215-811
8.	M-2 protocol (M 2)
9.	Yttrium
10.	pentetreotide (OctreoScan)
19 Drugs and Important Bio-Agents and 27 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Radiotherapy
3.	Brachytherapy
3 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>